Stock Report

Download full stock data and analysis for free Last Updated: 04-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Amryt Pharma (AMYT) Key Ratios

Stock Card factsheet share-fund-plan-icon

$14.70

$0.00 (0.00%)

As on 21-Apr-2023 09:30EDT

Market cap

info icon

$943 Mln

Revenue (TTM)

info icon

$244 Mln

P/E Ratio

info icon

39.7

P/B Ratio

info icon

1.4

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -10.81 8.15 19.23 137.87 174.77
EBIT -58.22 57.13 104.14 6.96 -191.39
Net Profit -195.01 -20.84 83.08 11.43 -173.46
EPS -195.01 -0.07 93.77 -- --
Book Value -- -- 233.18 -- --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-21Dec-20
EBIT-Margin info -32.21-92.631.54-9.72-24.89
Net Margin info -----8.19----
Return on equity info -73.43-116.90-5.96-9.00-106.95
Return on Capital info -27.45-55.21---4.59-37.18
Return on Assets info -14.53-23.00-2.11-2.75-19.52
Debt to Equity (x) info ----0.640.592.85

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
--
-4.59
-37.18
-40.57
-108.63
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-5.96

Lower than Peers by 24.93

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
-5.96
-9.00
-106.95
-104.33
-261.40
Peer Median
18.97
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-2.11

Lower than Peers by 4.97

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
-2.11
-2.75
-19.52
-21.31
-33.34
Peer Median
2.86
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

1.54

Lower than Peers by 14.28

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
1.54
-9.72
-24.89
-62.01
-168.60
Peer Median
15.82
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-8.19

Lower than Peers by 16.43

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
-8.19
-8.17
-57.24
-112.75
-178.34
Peer Median
8.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

19.23

Higher than Peers by 11.18

Year on year growth in net sales

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
19.23
0.22
2.14
2.52
0.08
Peer Median
8.05
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

104.14

Higher than Peers by 95.88

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
104.14
52.38
-26.08
-29.30
8.13
Peer Median
8.26
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

83.08

Higher than Peers by 75.35

Year on year growth in profit after tax

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
83.08
82.62
-59.50
-122.26
5.96
Peer Median
7.73
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

93.77

Higher than Peers by 83.37

Year on year growth in earnings per share

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
93.77
0.89
--
--
--
Peer Median
10.39
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-12.25

Lower than Peers by 17.12

Year on year growth in book value per share

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
-12.25
--
--
--
--
Peer Median
4.87
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

0.64

Higher than Peers by 0.05

Total debt / Net worth

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
0.64
0.59
2.85
1.38
-5.14
Peer Median
0.59
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.00

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
0.00
--
0.01
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

1.57

Lower than Peers by 0.08

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
1.57
1.80
2.01
1.47
1.60
Peer Median
1.65
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

0.94

Lower than Peers by 0.26

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
0.94
1.06
1.60
1.03
1.42
Peer Median
1.20
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

0.23

Lower than Peers by 4.54

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
0.23
-0.78
-2.32
-4.25
-17.76
Peer Median
4.77
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

20.86

Lower than Peers by 0.42

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
20.86
24.22
23.65
62.60
35.83
Peer Median
21.27
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.26

Lower than Peers by 0.14

Sales / Average Total Assets

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
0.26
0.34
0.34
0.19
0.19
Peer Median
0.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
--
79.68
79.58
132.94
128.10
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
--
269.78
129.82
198.97
103.54
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
--
225.95
174.38
125.03
330.68
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-21
Dec-20
Dec-19
Dec-18
Amryt Pharma (AMYT)
--
123.51
35.03
206.88
-99.04
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...